Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

CorMedix (CRMD) EBITDA Margin (2016 - 2025)

CorMedix has reported EBITDA Margin over the past 12 years, most recently at 0.07% for Q4 2025.

  • Quarterly results put EBITDA Margin at 0.07% for Q4 2025, down 7.0% from a year ago — trailing twelve months through Dec 2025 was 0.03% (down 2.0% YoY), and the annual figure for FY2025 was 0.03%, down 2.0%.
  • EBITDA Margin reached 0.07% in Q4 2025 per CRMD's latest filing, down from 0.01% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 0.28% in Q2 2024 and bottomed at 100446.94% in Q3 2022.
  • Median EBITDA Margin over the past 4 years was 8180.42% (2021), compared with a mean of 23831.51%.
  • Peak annual rise in EBITDA Margin hit 2072558bps in 2022, while the deepest fall reached -8442570bps in 2022.
  • Over 4 years, EBITDA Margin stood at 13829.39% in 2021, then crashed by -99bps to 27513.23% in 2022, then skyrocketed by 100bps to 0.01% in 2024, then crashed by -1137bps to 0.07% in 2025.
  • Business Quant data shows EBITDA Margin for CRMD at 0.07% in Q4 2025, 0.01% in Q3 2025, and 0.01% in Q2 2025.